Cigna Group Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 24, 2022, discloses a material change to Cigna Corporation's segment reporting structure effective in the fourth quarter of 2021. The change aligns with the pending sale of Cigna's life, accident, and supplemental benefits businesses in seven countries to Chubb INA Holdings, Inc. for $5.75 billion (the "Chubb Transaction").
The filing provides restated financial data for the nine months ended September 30, 2021, and full years ended December 31, 2020 and 2019, to reflect the new reporting basis.
Key Financial Metrics (Nine Months Ended Sept 30, 2021)
Financial results are presented on a restated segment basis. All figures are in millions unless otherwise noted.
| Metric | Evernorth | Cigna Healthcare | Corporate & Other | Cigna Total |
|---|---|---|---|---|
| Total Revenues | $96,826 | $33,426 | $(1,862) | $128,390 |
| Adjusted Revenues | $96,826 | $33,438 | $(1,862) | $128,402 |
| Income from Operations | $2,757 | $3,082 | $559 | $6,398 |
| Shareholders' Net Income | $4,249 | |||
| Adjusted Income from Operations | $5,408 |
Note: "Corporate and Other Operations" includes negative revenue due to eliminations and the classification of exiting businesses.
Material Changes and Segment Restructuring
The primary material change is the reclassification of business segments to separate retained operations from those being sold to Chubb.
- New Cigna Healthcare Segment: Aggregates the former U.S. Medical segment with the retained businesses from the former International Markets segment (now International Health). This segment includes U.S. Commercial, U.S. Government, and International Health operations.
- Other Operations: Now houses the businesses to be sold to Chubb (International Life, Accident, and Supplemental Benefits in seven countries), as well as run-off businesses (Reinsurance, Settlement Annuity, Individual Life) and Corporate-Owned Life Insurance.
- Evernorth Segment: Remains unchanged, covering pharmacy solutions, benefits management, care solutions, and intelligence solutions.
Restated results show that for the nine months ended September 30, 2021, the Cigna Healthcare segment reported total revenues of $33.4 billion and income from operations of $3.1 billion under the new basis.
Outlook, Risks, and Management Commentary
Transaction Status: Cigna expects to complete the $5.75 billion sale to Chubb during 2022, subject to regulatory approvals and customary closing conditions.
Forward-Looking Risks: The filing highlights several risks that could cause actual results to differ from expectations, including:
- Impact of the COVID-19 pandemic on operations and financial condition.
- Regulatory and political risks affecting multinational operations and government-sponsored programs (e.g., Medicare).
- Price competition and margin compression.
- Risks related to the realization of benefits from strategic transactions, including the Chubb sale.
- Cybersecurity threats and data privacy incidents.
- Significant indebtedness and potential for further indebtedness.
Conference Call: Management hosted a conference call on January 24, 2022, to discuss the segment reporting changes.
Investor Verification Checklist
- Transaction Closing: Verify the status of regulatory approvals for the $5.75 billion Chubb Transaction and the expected closing timeline in 2022.
- Segment Comparability: Confirm that future financial reports will strictly adhere to the new segment definitions (Cigna Healthcare, Evernorth, Corporate & Other) to ensure accurate period-over-period analysis.
- Adjusted Metrics: Review the reconciliation between GAAP measures (Shareholders' Net Income) and non-GAAP measures (Adjusted Income from Operations) to understand the impact of special items, amortization, and investment gains/losses.
- Run-off Liabilities: Assess the financial impact of the "Other Operations" segment, which includes run-off businesses and exiting operations, on future cash flows and earnings.
- Debt Levels: Monitor the company's debt extinguishment costs (noted as $141 million in the nine months ended Sept 30, 2021) and overall leverage in light of the pending transaction proceeds.